Keyphrases
Acute Lymphoblastic Leukemia
100%
Decitabine
100%
Chemosensitizer
100%
Epigenetics
25%
Synergistic Effect
25%
Acute Lymphoblastic Leukemia Cells
25%
DNA Methyltransferase Inhibitor
25%
MEK Inhibitor (MEKi)
12%
Leukemia
12%
L-asparaginase
12%
Histone Deacetylase Inhibitor (HDACi)
12%
Cytarabine
12%
Anticancer Drugs
12%
Daunorubicin
12%
Leukemia Subtype
12%
Venetoclax
12%
Antileukemic Activity
12%
High-throughput
12%
Receptor Tyrosine Kinase
12%
Prolonged Survival
12%
Panobinostat
12%
Prednisolone
12%
DNA Methylation Pattern
12%
Xenograft Mice
12%
Antineoplastic Agents
12%
Highly Aggressive
12%
Conventional Chemotherapy
12%
Drug Library
12%
Xenograft Mouse Model
12%
Aberrant DNA Methylation
12%
Bcl-2 Inhibitor
12%
Prolonged Exposure
12%
Conventional Drugs
12%
Foretinib
12%
Pimasertib
12%
Library Screen
12%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Decitabine
100%
DNA Methyltransferase Inhibitor
25%
Mouse Model
12%
Vincristine
12%
Chemotherapy
12%
Anticarcinogen
12%
Daunorubicin
12%
Cytarabine
12%
Leukemia
12%
Venetoclax
12%
Asparaginase
12%
Histone Deacetylase Inhibitor
12%
Panobinostat
12%
Protein Tyrosine Kinase
12%
Prednisolone
12%
Long Term Exposure
12%
Mitogen Activated Protein Kinase Kinase Inhibitor
12%
Scanning Electron Microscopy
12%
Foretinib
12%
Pimasertib
12%
Biochemistry, Genetics and Molecular Biology
Sensitization
100%
Decitabine
100%
Low Drug Dose
37%
DNA Methyltransferase
25%
Epigenetics
25%
Asparaginase
12%
DNA Methylation
12%
Mouse Model
12%
Anticancer
12%
Receptor Tyrosine Kinase
12%
MEK Inhibitor
12%
Scanning Electron Microscopy
12%
Daunorubicin
12%
Histone Deacetylase
12%
Prednisolone
12%
Cytarabine
12%